학력

• 1983 - 1987 서울대학교 미생물학과, 이학사
• 1987 - 1989 Department of Microbiology, University of Illinois-Urbana/Champaign, M. S.
• 1987 - 1992 Department of Microbiology, University of Illinois-Urbana/Champaign, Ph. D.

주요 경력

• 1993-1994 Department of Molecular and Cell Biology, University of California-Berkeley, USA, 포스트닥
• 1994-현재 한국외국어대학교 생명공학과 조교수, 부교수, 교수
• 2002-2002 한국 미생물생명공학회 국제간사
• 2003-2003 한국 분자세포생물학회 복지운영위원
• 2004-2004 한국 미생물생명공학회 학술간사
• 2006-2006 한국 미생물학회 국제협력위원
• 2007-2007 한국 미생물생명공학회 국제간사
• 2007-2007 한국 생화학분자생물학회 뉴스지편집위원
• 2008-2008 한국 미생물생명공학회 재무간사
• 2010-2010 한국 미생물생명공학회 총무간사
• 2009-2013 서울대학교 융합기술원 겸임연구원
• 2003-2010 (주) 이매진 연구위원
• 2010-2012 한국외국어대학교 교무처장
• 2010-현재 박테리오페이지 소재은행 센터장
• 2012-2012 한국미생물학회 총무운영위원
• 2015-2015 한국미생물학회연합 사무총장
• 2016-2016 한국미생물생명공학회 기획간사
• 2017-2017 한국미생물생명공학회 간사장
• 2016-2019 한국외국어대학교 연구산학협력단장
• 2019 과기부 국가 바이러스연구소 설립기획 자문위원
• 2019 ㈜ 라이센텍 설립 (http://www.lysentech.com)
• 2022-현재 Phage Australia Chief Investigator

Editorial Role

• Associate editor, Frontiers in Microbiology
• Topic editor, Viruses

연구 분야

• Bacteriophage therapy
• Immune response to bacteriophages
• Oncolytic phage
• Phage display

최근 논문

• Hong H-W, Jang J, KIm YD, Jeong T-H, Lee D, Park K, Kim MS, Yoon I-S, Song M, Seo M-D, Yoon H, Lim D, Myung H. 2025. In vitro and in vivo efficacy studies of an engineered endolysin targeting Gram-negative pathogens. International Journal of Biological Macromolecules 302:140463
• Cho Y, Park K, Park J, An J, Myung H, Yoon H. 2024. Exploring the therapeutic potential of endolysin CD27L_EAD against Clostridioides difficile infection. International Journal of Antimicrobial Agents 64:107222
• Lim J, Myung H, Lim D, Song M. 2024. Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model. Journal of Biomedical Science 31:36-44
• Cho J, Hong H-W, park K, Myung, H, Yoon H. 2024. Unveiling the mechanism of bactericidal activity of a cecropin A-fused endolysin LNT113. International Journal of Biological Macromolecules 260:129493
• Lee S, Lynch S, Lin RC, Myung H, Iredell J. 2024. Phage Therapy in Korea: A Prescribers' Survey of Attitudes Amongst Korean Infectious Diseases Specialists Towards Phage Therapy. Infection and Chemotherapy 55:e54
• Jeong TH, Hong H-W, Kim MS, Song M, Myung H. 2023. Characterization of three different endolysins effective against Gram-negative bacteria. Viruses 15:679
• Seo S-W, Han D-G, Baek YM, Park MC, Yoo J-W, Jung Y, Maeng H-J, Myung H, Yoon I-S. 2023. Investigation of the factors responsible for the low oral bioavailability of alizarin using a sensitive LC‐MS/MS method: In vitro, in situ, and in vivo evaluations. Drug Development Research 2023:1-13
• Hwang YJ, Jo J, Kim E, Yoon H, Hong H-W, Kim MS, Myung H. 2022. Motility increase of Adherent Invasive Escherichia coli (AIEC) induced by a sub-inhibitory concentration of recombinant endolysin LysPA90. Frontiers in Microbiology 13:1093670
• Hong H-W, Kim YD, Jang, J, Kim MS, Song M, Myung, H. 2022. Combination effect of engineered endolysin EC340 with antibiotics. Frontiers in Microbiology 13:821936
• Oh HK, Hwang YJ, Hong HW, Myung H. 2021. Comparison of Enterococcus faecalis Biofilm Removal Efficiency among Bacteriophage PBEF129, Its Endolysin, and Cefotaxime. Viruses 13:426
• Hwang YJ, Myung H. 2020. Engineered bacteriophage T7 as a potent anticancer agent in vivo. Frontiers in Microbiology, 11:491001
• Oh HK, Cho J, Hwang YJ, Myung H. 2020. Complete genome sequence of a novel bacteriophage, ATCEA85, infecting Enterobacter aerogenes. Arch. Virol. 165:2397-240
• Oh HK, Cha K, Hwang YJ, Cho J, Jo Y, Myung H. 2019. Complete genome sequence of a novel bacteriophage, PBKP05,infecting Klebsiella pneumoniae. Arch. Virol. 164:885-888
• Kim MJ, Jo Y, Hwang YJ, Hong HW, Hong SS, Park K, Myung H. 2018. Phage-antibiotic synergy via delayed lysis. Appl. Environ. Microbiol. 84: e02085-18
• Cha K, Oh HK, Jang JY, Kim WK, Jo YY, Ha GU, Ko KS, Myung H. 2018. Characterization of two novel bacteriophages infecting multidrug-resistant (MDR) Acinetobacter baumannii and evaluation of their therapeutic efficacy in vivo. Frontiers in Microbiology. 9:696
• Lee HJ, Kim WI, Kwon YC, Cha KE, Kim M, Myung H. 2016. A newly isolated bacteriophage, PBES 02, infecting Cronobacter sakazakii. J. Microbiol. Biotechnol. 26:1629-1635
• Moon J, Kaowinn S, Cho IR, Myung H, Oh S, Kaewpiboon C, Kraemer OH, Ching Y-H. 2016. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through downregulation of HDAC4. Biochem. Biophys. Res. Comm. 474:428-434
• Kim YD, Jo YY, Myung H. 2016. Removal of Staphylococcus aureus from various surfaces using bacteriophage SA11. Res. J. Biotechnol. 11:130-137
• Kim MS, Kim YD, Hong SS, Park K, Ko KS, Myung H. 2015. Phage Encoded Colanic Acid-Degrading Enzyme Permits Lytic Phage Infection of a Capsule-Forming Resistant Mutant Escherichia coli Strain. Appl. Environ. Microbiol. 81:900-909
• Park K, Cha KE, Myung H. 2014. Inflammatory responses of mice orally fed with bacteriophage T7. J. Appl. Microbiol. 117:627-633
• Kim MS, Kim YD, Myung H. 2014. Characterization of phage PA26 infecting Pseudomonas aeruginosa. J. Pure Applied Microbiol. 8:35-41
• Kim MS, Kim S, Myung H. 2014. Degradation of AIMP1/p43 Induced by Hepatitis C Virus E2 Leads to Upregulation of TGF-β Signaling and Increase in Surface e-x-p-r-e-s-s-i-o-n of gp96. PLOS ONE 9(5):e96302
• Hong SS, Jeong J, Lee J, Kim S, Min WG, Myung H. 2013. Therapeutic Effects of Bacteriophages against Salmonella gallinarum Infection in Chickens. J. Microbiol. Biotechnol. 23:1478-1483
• Kim MS, Hong SS, Park K, Myung H. 2013. Genomic analysis of bacteriophage PBECO4 infecting Escherichia coli O157:H7. Arch. Virol. 158:2399-2403
• Hong H-W, Lee S-W, Myung H. 2013. Induced degradation of Tat by nucleocapsid (NC) via the proteasome pathway and its effect on HIV transcription. Viruses 5:1143-1152
• Hong J-Y, Hwang Y-K, Kye YM, Myung H, Won YS, Huh S. 2013. Hierarchially structured functionalizable mesoporous PEDOT-derived conducting polymers. Materials Letters 96:181-184
• Kim MS, Cha KE, Myung H. 2012. Complete genome of Staphylococcus aureus phage SA11. J. Virol. 86:10232
• Kim MS, Myung H. 2012. Complete genome of Pseudomonas aeruginosa phage PA26. J. Virol. 86:10244
• Lee CH, Kim JH, Kim H, Myung H, Lee SW. 2012. Hepatitis C Virus Replication-Specific Inhibition of MicroRNA Activity with Self-Cleavable Allosteric Ribozyme. Nucleic Acid Therapeutics 22:17-29
• Han D, Huh S, Myung H. 2011. Selection and characterization of peptides binding to divalent cations. J. Peptide Sci. 17:565-168
• Lee JH, Lee S, Park MY, Myung H. 2011. Characterization of Thiobarbituric Acid Derivatives as Inhibitors of Hepatitis C Virus NS5B Polymerase. Virol. J. 8:18.
• Hong HW, Lee SW, Myung H. 2010. Selection of peptides binding to HCV E2 and inhibiting viral infectivity. J. Microbiol. Biotechnol. 20:1769-1771
• Lee JH, Lee S, Park MY, Ha HJ, Myung H. 2010. Evaluation of Inhibitory Effects of Thiobarbituric Acid Derivatives Targeting HCV NS5B Polymerase. J. Microbiol. Biotechnol. 20:510-512
• Myung H, Han J, Kim S. 2010. Antitumor activity and pharmacokinetic properties of ARS-interacting multifunctional protein 1 (AIMP1/p43). Cancer Lett. 287:157-164
• Lee JH, Cha K, Kim M, Hong HW, Jung D, Ryu G, Myung H. 2009. Nano-sized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicol. Lett. 190:202-207.

특허 등록

• HCV 자가 복제효소 활성의 세포 내 측정용 키트 및 측정 방법 -등록 0447578 (2004.09.23)
• HIV-1의 누클레오캡시드 단백질과 결합할 수 있는 단백질 -등록 0451565 (2004.08.27)
• 인간의 면역결핍 바이러스 psi RNA 염기서열에 특이적으로 결합하는 펩티드 -등록 0498912 (2005.06.23)
• Ｃ형 간염 바이러스의 중합효소 ＮＳ５Ｂ를 저해하는 C형 간염 바이러스 치료제 -등록 1009457840000 (2010.2.26)
• C형간염바이러스의 표면단백질 이2에 부착하는 7개의 아미노산으로 이루어진 펩티드 -등록 10-1035799 (2011)
• C형간염바이러스의 표면단백질 이2에 부착하는 12개의 아미노산으로 이루어진 펩티드 -등록 10-1156338 (2012)
• 납이온에 부착하는 7개의 아미노산으로 이루어진 펩티드 -등록 10-1156304 (2012)
• 납이온에 부착하는 7개의 아미노산으로 이루어진 펩티드 2 -등록 10-1156242 (2012)
• 슈도모나스 에루기노사의 박테리오파아지 및 그 용도 -등록 10-1382893 (2014. 4. 1)
• 살모넬라 엔테리카의 박테리오파아지 및 그 용도 -등록 10-1449417 (2014. 10. 2)
• 박테리오파아지 PBECO4 또는 그 유래의 콜라닌산 분해효소를 포함하는 박테리오파지 내성 박테리아 감염용 조성물 및 그 용도 - 등록 10-1607395 (2016.3.23)
• 슈도모나스 에루기노사의 박테리오파지 PA7 -등록 10-1612607 (2016.4.7)
• 반응성 산소종을 포함하는 박테리오파아지의 생산량 증가 조성물 및 방법 -등록 10-1909831 (2018. 10. 12)
• PCT 출원, 반응성 산소종을 포함하는 박테리오파아지의 생산량 증가 조성물 및 방법 (PCT/KR2018/ 009663) (2018. 8. 22)
• Oncolytic T7 bacteriophage having cytokine gene and displaying homing peptide on capsid and its use for treating cancer (미국특허 출원 16/685,516) (2019. 11. 15)
• 캡시드에 귀소 펩타이드를 디스플레이하고 사이토카인 유전자를 포함하는 종양 용해성 재조합
• 박테리오파아지 및 이의 암치료용 용도- 등록 10-2209906 (2021.1.26.)
• 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제 - 등록 10-2224897 (2021.3.2.)
• 폴리펩타이드 변이체 및 이를 포함하는 그람음성균에 대한 항생제 – 등록 10-2228999 (2021.3.11.)
• 신규한 폴리펩타이드 및 이를 포함하는 엔테로코커스 속 세균에 대한 항생제 – 등록 10-2224896 (2021.3.2.)
• Oncolytic T7 bacteriophage having cytokine gene and displaying homing peptide on capsid and its use for treating cancer 등록 US 11,384,338 (2022.07.12)
• Novel polypeptides, fusion polypeptide, and antibiotic against Gram-negative bacteria comprising same 등록 ZL 202180018132.5 (2023.02.10)
• Polypeptides, fusion polypeptide, and antibiotic against Gram-negative bacteria comprising same 등록 US 11,807,881 (2023.11.07)
• Polypeptides and antibiotics against Gram-negative bacterium comprising the same 등록 ZL 202210999482.0 (2023.11.10)
• COMPOSITION AND METHOD FOR INCREASING PRODUCTION OF BACTERIOPHAGE, USING REACTIVE OXYGEN SPECIES 등록 US 11,899,171 (2024.02.13)
• COMPOSITION AND METHOD FOR INCREASING PRODUCTION OF BACTERIOPHAGE, USING REACTIVE OXYGEN SPECIES 등록 EP 3677671 (2024.08.21)
• Novel polypeptides and antibiotics against Gram-negative bacterium comprising the same 등록 US 12,102,667 (2024.10.01)
• Novel polypeptides, fusion polypeptide, and antibiotic against Gram-negative bacteria comprising same 등록 JP 7584162 (2024.11.07)

수행 중인 과제

• LNT113 엔도라이신을 이용한 신규 항생제의 개발 (보건복지부)
• LNT103을 흡입형 항생제로 개발 (산업통상자원부)
• GloPID-R 국제협력연구 (과학기술정보통신부)

Education

• 1987 B. S. in Microbiology, Seoul National University
• 1992 Ph. D. in Microbiology, University of Illinois-Urbana/Champaign

Career

• 1993-1994 Postdoc. University of California-Berkeley
• 2008-2010 Director, ImaGene
• 2010-2012 Dean, Academic Affairs, HUFS
• 2010-present Director, The Bacteriophage Bank of Korea
• 2017 Chief Secretary, Korean Society of Microbiology and Biotechnology
• 2016-2109 Dean, R&DB Foundation, HUFS
• 2019-present CEO, LyseNTech
• 2022-present Chief Investigator, Phage Australia

Editorial role

• Associate editor, Frontiers in Microbiology
• Topic editor, Viruses

Research interests

• Bacteriophage
• Phage therapy
• Phage-immune system interaction

Recent publications

• Hong H-W, Jang J, KIm YD, Jeong T-H, Lee D, Park K, Kim MS, Yoon I-S, Song M, Seo M-D, Yoon H, Lim D, Myung H. 2025. In vitro and in vivo efficacy studies of an engineered endolysin targeting Gram-negative pathogens. International Journal of Biological Macromolecules 302:140463
• Cho Y, Park K, Park J, An J, Myung H, Yoon H. 2024. Exploring the therapeutic potential of endolysin CD27L_EAD against Clostridioides difficile infection. International Journal of Antimicrobial Agents 64:107222
• Lim J, Myung H, Lim D, Song M. 2024. Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model. Journal of Biomedical Science 31:36-44
• Cho J, Hong H-W, park K, Myung, H, Yoon H. 2024. Unveiling the mechanism of bactericidal activity of a cecropin A-fused endolysin LNT113. International Journal of Biological Macromolecules 260:129493
• Lee S, Lynch S, Lin RC, Myung H, Iredell J. 2024. Phage Therapy in Korea: A Prescribers' Survey of Attitudes Amongst Korean Infectious Diseases Specialists Towards Phage Therapy. Infection and Chemotherapy 55:e54
• Jeong TH, Hong H-W, Kim MS, Song M, Myung H. 2023. Characterization of three different endolysins effective against Gram-negative bacteria. Viruses 15:679
• Seo S-W, Han D-G, Baek YM, Park MC, Yoo J-W, Jung Y, Maeng H-J, Myung H, Yoon I-S. 2023. Investigation of the factors responsible for the low oral bioavailability of alizarin using a sensitive LC‐MS/MS method: In vitro, in situ, and in vivo evaluations. Drug Development Research 2023:1-13
• Hwang YJ, Jo J, Kim E, Yoon H, Hong H-W, Kim MS, Myung H. 2022. Motility increase of Adherent Invasive Escherichia coli (AIEC) induced by a sub-inhibitory concentration of recombinant endolysin LysPA90. Frontiers in Microbiology 13:1093670
• Hong H-W, Kim YD, Jang, J, Kim MS, Song M, Myung, H. 2022. Combination effect of engineered endolysin EC340 with antibiotics. Frontiers in Microbiology 13:821936
• Oh HK, Hwang YJ, Hong HW, Myung H. 2021. Comparison of Enterococcus faecalis Biofilm Removal Efficiency among Bacteriophage PBEF129, Its Endolysin, and Cefotaxime. Viruses 13:426
• Hwang YJ, Myung H. 2020. Engineered bacteriophage T7 as a potent anticancer agent in vivo. Front. Microbiol. 11: 491001
• Oh HK, Cho J, Hwang YJ, Myung H. 2020. Complete genome sequence of a novel bacteriophage, ATCEA85, infecting Enterobacter aerogenes. Arch. Virol. 165:2397-2400
• Oh HK, Cha K, Hwang YJ, Cho J, Jo Y, Myung H. 2019. Complete genome sequence of a novel bacteriophage, PBKP05, infecting Klebsiella pneumoniae. Arch. Virol. 164:885-888
• Kim MJ, Jo Y, Hwang YJ, Hong HW, Hong SS, Park K, Myung H. 2018. Phage-antibiotic synergy via delayed lysis. Appl. Environ. Microbiol. 84(22). pii: e02085-18
• Cha K, Oh HK, Jang JY, Kim WK, Jo YY, Ha GU, Ko KS, Myung H. 2018. Characterization of two novel bacteriophages infecting multidrug-resistant (MDR) Acinetobacter baumannii and evaluation of their therapeutic efficacy in vivo. Front. Microbiol. 9:696
• Lee HJ, Kim WI, Kwon YC, Cha KE, Kim M, Myung H. 2016. A newly isolated bacteriophage, PBES 02, infecting Cronobacter sakazakii. J. Microbiol. Biotechnol. 26:1629-1635
• Moon J, Kaowinn S, Cho IR, Myung H, Oh S, Kaewpiboon C, Kraemer OH, Ching Y-H. 2016. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through downregulation of HDAC4. Biochem. Biophys. Res. Comm. 474:428-434
• Kim YD, Jo YY, Myung H. 2016. Removal of Staphylococcus aureus from various surfaces using bacteriophage SA11. Res. J. Biotechnol. 11:130-137
• Kim MS, Kim YD, Hong SS, Park K, Ko KS, Myung H. 2015. Phage Encoded Colanic Acid-Degrading Enzyme Permits Lytic Phage Infection of a Capsule-Forming Resistant Mutant Escherichia coli Strain. Appl. Environ. Microbiol. 81:900-909